Cyclone® 18/9 - IBA Radiopharma Solutions

Cyclone® 18/9
Moving Ahead, delivering More
IBA Molecular
Cyclone® 18/9 |
Cyclone® 18/9
Maximizing Your Potential |
“The Cyclone® 18/9 has met our Centre’s
expectations as a reliable and a stable
machine, producing ample radioisotopes
for our existing customers. Importantly, the
Cyclone® 18/9 has sufficient capacity and
flexibility to continue to meet increased
isotope demand for the foreseeable future,
strengthening our position as the number
one supplier in our region.
The user friendliness of the IBA operational
system has enabled us to establish a broad
team of skilled operators to ensure that the
facility remains operational, even at times
when the availability of some of our staff is
reduced, which occurs in busy hospitals.
The personal response and follow-up from
individual IBA staff has greatly assisted
our Centre’s technical understanding
and problem solving capabilities for the
Cyclone® 18/9, which is demonstrated by
our Centre’s up-time and isotope delivery
rates.
What is your greatest potential ?
■ To maximize your production capacity, while protecting your team ?
■ To stay ahead by producing an expanded line of radioisotopes ?
■ To complete your project on time ?
What if you could find a partner to help you maximize your greatest potential ?
Wouldn’t your choice be simple ?
We have no hesitation in recommending
IBA as a partner for PET radioisotope
production.”
Thomas Tuchyna
Cyclotron Manager
Sir Charles Gairdner Hospital, Perth, Australia
|2
Cyclone® 18/9 -HC |
Recurrent, fast and high
production capacity.
IBA Molecular | 3 |
The Cyclone® 18/9 -ST (STandard) is built with an upgradeready configuration to offer a painless and cost-effective
upgrade to the Cyclone® 18/9 -HC (High Current) model at a
later stage, if required.
Cyclone 18/9
Maximizing Your Potential |
®
The IBA Molecular Cyclone® 18/9
maximizes your potential.
Enhance |
More capacity, better safety
Selecting a cyclotron is a long-term
decision that will affect your production
capacity, thus your profitability.
The Cyclone® 18/9 offers the most vital
success factors.
Operational and cost efficiency
■ High energy : 18 MeV protons
■ High current : up to 150 μA
■ High yield targets : up to 15 Ci 18F -
Safety and comfort
■ Low exposure with distributed
targets around the cyclotron
■ Quick disconnect targets
for easy maintenance
■ Redundant and instant exchange
of foil extraction system
■ Long-life ion source
■ Extra-stable dual beam mode
using harmonic coils
Cyclone® 18/9 |
Fitted with Vectio® external beam line
for advanced research.
|4
Discover |
A new world of research
Integrate |
IBA Molecular has used its expertise to
create the features of the Cyclone® 18/9
to give you access to the widest range of
PET radiotracers.
More expertise
A full range of target technology
■ Eight targets for more flexibility
■ Standard deuteron beam for
production of 15O, 18F2 radioisotopes
■ Nirta® Solid target technology for
novel radioisotopes: 124I, 64Cu, ...
External beam line for research
■ Available in various configurations
Turn your most advanced project into
reality by employing the IBA global
solution for a turnkey cyclotron facility
and expertise in full pharmaceutical
engineering.
Global solution
■ Facility and Process equipment
■ Radiation safety calculations
■ cGMP validation
■ Financing solutions
■ Training programs
■ Enhance research opportunities
by use of own customised target
system
■ Ideal educational tools (fundamental
physics, ...).
Become exclusive research partner
■ You will be afforded the unique
opportunity to participate in a
worldwide collaborative network
that is focused on the future of
molecular imaging.
Turnkey Offering |
A complete solution to meet all your
radioisotope production needs.
IBA Molecular | 5 |
Cyclone® 18/9
Maximizing Your Potential |
Technical Features |
Cyclone® 18/9 -ST
Typical Production Yields - PET Isotopes
Isotope Chemical
Form
C
11
CO2
Target
Reaction
Target Material
N(p,α) C
N2+ 0.5-1% O2
14
11
13
15
N
O2
NH3
O2
High capacity
Target
Size
16
14
O(p,α)13N
30
15
N2+ 0.5% O2 
N(d,n) O
15
on line  
N2+ 2% CO2
60
1 200
Te O2 (>99.9%)
300
50
Ni (> 99%)
120
600
H218O
(98%)
F
XL
2XL
3XL(2)
Ne(d,α)18F
F2
I
NaI
Cu
CuCl
124
64
18
Te(p,n)124I
Ni(p,n) Cu
64
18
124
64
100 µA
40 µA
Dual P.I.G.(3) sources
150 µA
40 µA
Dual P.I.G.(3) sources
Extra-stable dual beam(4)
Powerful and efficient RF amplifier
Target flexibility
Number of target ports
Simultaneous extracted beams
Nirta® Fluor Target: large range
of volumes
Nirta® Solid Target
Vectio® Beam Transport Line
8
2
0.4 to 3 ml
8
2
0.4 to 3 ml
Non-conventional
PET isotopes
2 to 6 m
Non-conventional
PET isotopes
2 to 6 m
Low power consumption
Standby mode
< 6 kW
< 6 kW
Beam-on mode
< 45 kW
< 50 kW
Exclusive
international patent(4)
Exclusive
international patent(5)
Deep valley magnet
carrier
O2(p,n)18F2
124
64
Ne (natural) +F2
- proton
- deuteron
18 MeV
9 MeV
Eight independant dual stripper extraction system
(cont.flow)
O2
O(p,n)18F
18
Beam current
18 MeV
9 MeV
2 separate internal P.I.G ion sources
500/min
1 000
1 600
3 000
5 000
4 200
7 000
5 300
9 000
8 000
13 000
250
- protons
- deuterons
Reliability
400
60
60
60
120
60
120
60
120
60
120
60
Energy
Dual particle acceleration
400/min
L
20
3 000
(cont.flow)
S
M
18
Recovered
Activity(1)
EOB (mCi)
1 000
H2O (natural)
+ 5 mMol Ethanol
CO2
F¯
Irradiation
Time (min)
N2+ 5% H2
CH4
Cyclone® 18/9 -HC
Magnetic structure
Coils D.C. power
Mean field
< 15 kW
1.35 Tesla
< 15 kW
1.35 Tesla
Compact design
Total weight
Overall dimensions (dia. x height)
Minimal building opening
Minimal vault dimensions
25 Tons
2 x 2.2 m
2.4 x 2.4 m
4x4x3m
25 Tons
2 x 2.2 m
2.4 x 2.4 m
4x4x3m
Minimal exposure
Minimal activation with horizontal accelerating plane
Non clustered targets, naturally shielded by the yoke
Local target shielding doors (optional) for easier building decommissioning
(1) All values given in single beam mode
(2) Only available on Cyclone® 18/9 -HC.
|6
No Limits, Today and Tomorrow |
Can easily be upgraded to 150 µA.
(3) Penning Ion Gauge Technology
(4) International patent number: WO 2004/ 049770 A1
(5) International patent numbers EP 0 222 786 and US 4,771,208
IBA Molecular | 7 |
IBA activities
in a nutshell
IBA delivers solutions of
unprecedented precision in
the fields of cancer diagnosis
and therapy. The company also
offers sterilization and ionization
solutions to improve the hygiene
and safety of everyday life.
Diagnosis
IBA has unique expertise in the design of cyclotrons and
in the production and distribution of radiopharmaceutical
tracers which are used every day in hospitals to quickly
and accurately detect cancer, neurological and cardiac
diseases. IBA also offers dosimetry products used in
many hospitals for quality assurance in X-Ray diagnosis
and for patient-dose monitoring.
Therapy
IBA Molecular | Jan 2009 | Cyclone®18/9_R05 © IBA 2009 | All right reserved
IBA has developed Radiotherapy solutions and dosimetry
equipment to treat cancer with the greatest accuracy. IBA is
the undisputed leader in Particle Therapy, acknowledged to be
the most precise and effective clinical radiotherapy method in
the selective destruction of cancer cells.
Sterilization & Ionization
IBA designs electron accelerators and high power X-Ray
solutions used in many industries to sterilize medical devices,
to cold pasteurize food products and to improve polymer
properties. Over 250 IBA Industrial accelerators are used in
the world today, some for more than 40 years.
IBA, a Belgian company, is listed on the paneuropean
stock exchange EURONEXT and its Annual Reports can be
downloaded on the Website: www.iba-worldwide.com.
www.iba-worldwide.com
IBA Molecular, Europe
Chemin du Cyclotron, 3
1348 Louvain-la-Neuve, Belgium
Tel.: + 32 10 47 58 58
Fax: + 32 10 47 59 58
Info-cyclo@iba-group.com
IBA Molecular, North America
100 Executive Drive, Suite 100
Sterling, VA 20166
Tel.: + 1 703 787 7900
Fax: + 1 703 787 4079
IBA Molecular, China
No 258-1 Caochangdi
P.O. Box 100015-92
Chaoyang District
Beijing (P.R. China)
Tel.: + 86 10 64 34 46 40
Fax: + 86 10 84 56 02 25
While all care has been taken to ensure that the information contained in this
publication is correct, we accept no responsibility for any inaccuracy and reserve
the right to modify this information.
Technical specifications are based on standard operating conditions and may be
subject to variations.
Papier environment friendly.